Agendia, Inc.: Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project

Data show MammaPrint is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions

Related Keywords

United States ,San Antonio ,Texas ,American ,William Audeh ,Kostenloser Wertpapierhandel ,Sonya Reid ,Terri Clevenger ,American Society Of Clinical Oncology Annual Meeting ,Agendia Inc ,Linkedin ,Vanderbilt University Medical Center ,Twitter ,Facebook ,Department Of Medicine ,American Society ,Clinical Oncology Annual Meeting ,Vanderbilt University Medical ,San Antonio Breast Cancer Symposium ,Mammaprint Ultra Low ,Mammaprint High Risk ,Oncotypedx Recurrence Scores ,Recurrence Score ,Oncotypedx Recurrence Score Intermediate ,End Results ,Mammaprint High ,Mammaprint Low Risk ,High Risk ,World Evidence Trial ,Chief Medical Officer ,World Evidence ,Agendia ,Presents ,Data ,Rom ,Flex ,Meal ,World ,Evidence ,Trial ,Seven ,Posters ,Disco ,022 ,Howcasing ,Tower ,Patient ,Breast ,Dancer ,Enome ,Project ,